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Abstract 
 
ING family genes (Inhibitor of Growth) are tumor suppressor genes that play a vital role in 
cell homeostasis. It has been shown that their expression is lost or diminished in many cancers 
and other diseases. The main mechanisms by which they are regulated in oncogenesis have 
not yet been fully elucidated. The involvement of non-coding RNAs (ncRNAs) and in 
particular microRNAs (miRNAs) in post-transcriptional gene regulation is well established. 
miRNAs are short sequences (18 to 25 nucleotides) that can bind to the 3 'UTR sequence of 
the targeted messenger RNA (mRNA), leading to its degradation or translational repression. 
Interactions between the ING family and miRNAs have been described in some cancers but 
also in other diseases. The involvement of miRNAs in ING family regulation opens up new 
fields of investigation, particularly for targeted therapies. In this review, we will summarize 
the regulatory mechanisms at the RNA and protein level of the ING family and focus on the 
interactions with ncRNAs. 
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Abstract 
ING family genes (Inhibitor of Growth) are tumor suppressor genes that play a vital role in 
cell homeostasis. It has been shown that their expression is lost or diminished in many cancers 
and other diseases. The main mechanisms by which they are regulated in oncogenesis have 
not yet been fully elucidated. The involvement of non-coding RNAs (ncRNAs) and in 
particular microRNAs (miRNAs) in post-transcriptional gene regulation is well established. 
miRNAs are short sequences (18 to 25 nucleotides) that can bind to the 3 'UTR sequence of 
the targeted messenger RNA (mRNA), leading to its degradation or translational repression. 
Interactions between the ING family and miRNAs have been described in some cancers but 
also in other diseases. The involvement of miRNAs in ING family regulation opens up new 
fields of investigation, particularly for targeted therapies. In this review, we will summarize 
the regulatory mechanisms at the RNA and protein level of the ING family and focus on the 
interactions with ncRNAs. 
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Introduction  
p33ING1 was discovered in 1996 and identified as a candidate tumor suppressor gene 
(TSG) (1). The other members of the ING family were identified by homology search, and 
were then named ING2-ING5 (2–4). All INGs proteins share a conserved C-term (Carboxyl-
terminus) structure that contains a Plant HomeoDomain (PHD), known to interact with the 
histone 3 trimethylated on lysine 4 (H3K4me3) (5). They also have a Nuclear Localisation 
Signal (NLS) (6) and therefore, the ING proteins are mainly located in the nucleus. INGs are 
well-conserved from yeast to humans as suggested by phylogenetic studies (6,7), which 
implies an important role in biological processes. Indeed, by regulating the expression of 
genes, they are known to play a role in the cell cycle, senescence, apoptosis (5,8–11) and have 
therefore been classified as “gatekeepers” Tumor Suppressor Genes (TSG). ING proteins are 
able to promote apoptosis in a p53 dependent and independent manner (3,4,12). Moreover, 
ING1 and ING2 KO mice spontaneously develop tumors (13,14). More recently, they have 
also been shown to have “caretakers” properties by participating in DNA repair (15–18) and 
DNA replication (10,19,20).  
Since they are “gatekeeper and “caretaker” TSG, the family of INGs may play a role in 
many types of cancers such as lung, head and neck cancer, breast, ovarian, melanoma or brain 
(17,21–27). Indeed, they are usually lost or down-regulated in these types of cancer.  
Data summarized from The Cancer Genome Atlas and The Human Protein Atlas (Fig. 1) 
show that INGs RNA and protein expression vary according to tissue types and cancers. INGs 
protein are highly expressed in few tissues, and have usually a medium to low expression. 
RNA sequencing seems to be the most reliable method to compare INGs expression.  
The mechanisms that regulate INGs expression are just beginning to be understood. 
Although some mutations (Fig. 2) and LOH have been found (24,28–31), several recent 
studies have shown that non coding RNAs (ncRNAs) such as microRNAs (miRNAs) (32,33) 
can regulate of INGs. 
Non coding RNAs were discovered about 23 years ago in Caenorhabditis elegans (34). 
The discovery of several ncRNAs followed: microRNAs (miRNAs), transcribed ultra-
conserved regions (T-UCR) (35) and circular RNAs (circRNAs) which are highly conserved, 
and others which are less conserved such as long ncRNAs (lncRNAs) (36). miRNAs are 
short, about 18-25 nucleotide-long, and usually modulate the post-transcriptional gene 
expression by binding to seed sequences in the 3’-untraslated regions (3’-UTR) (37), thus 
suppressing mRNA translation and reducing mRNA stability. Since their discovery, miRNAs 
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have been implicated in many signaling pathways and various diseases (38–42) including 
cancers (43). In fact, some miRNAs can act as cancer enhancers and are usually called 
oncomiR, on the other hand, other can repress a cancerous phenotype and are classified as 
tumor suppressor miRNAs (44). For example, the miR-17-92 has been shown to be up-
regulated in several solid and hematopoietic cancers (45–48). Indeed, by targeting TSG, such 
as PTEN (49), miR-17-92 cluster containing miR-17-5p, miR-17-3p, miR-18a, miR-19a, 
miR-20a, miR-19b-1 and miR-92a-1, can promote oncogenesis, is associated with poor 
survival and thus is considered an oncomiR (46,47,50,51). In contrast, miR-217 is considered 
as tumor suppressor because its overexpression decreases cancer invasion and migration by 
targeting Enhancer of Zeste Homolog 2 (EZH2) in gastric cancer (52), known to enhance cell 
cycle or PTPN14, which modulates epithelial-to-mesenchymal transition (53).  
Recently, some lncRNAs have also been described as deregulated in cancer. In fact, the 
antisense RNA of the HOX transcript (HOTAIR) is a lncRNA which has been shown to be 
upregulated in several cancers such as brain, lung, colorectal, breast, ovarian, renal, 
hepatocellular and hematopoietic (54). Besides, its upregulation would enhance tumor 
progression (55) and lead to resistance to paclitaxel and doxorubicin in gastric cancer (56) by 
targeting the miR-217 tumor suppressor (57).  
This review describes the mechanisms responsible for the regulation of INGs and in 
particular the loss of expression of INGs in tumors and other diseases with a particular interest 
for the role that ncRNAs could play. 
 
I. INGs alteration in cancer and regulation of expression mechanisms 
Various causes explaining the loss or down regulation of the INGs protein in cancer such 
as mutations, Loss of Heterozygosity (LOH), hypermethylations, phosphorylations or 
SUMOylations have been described. However, those are not sufficient to explain the majority 
of INGs down regulation. It suggests that post-translational regulation such as ncRNA 
regulation could have an important impact on INGs regulation. 
 
1. INGs alteration of expression in cancer 
INGs expression is lost or decreased in several types of cancer, such as non-small cell 
lung cancer, breast, ovarian, hepatocellular cancer or osteosarcoma (21,23,58). Some 
mutations have been reported in the TCGA database, (0,2 %-9,43 % for ING1, 0,10 %-2,45 % 
for ING2, 0,2%-8,3% for ING3, 0,2-3,21% for ING4 and 0,2-5,85% for ING5), and are 
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summarized in Figure 1. Interestingly, mutations are more frequent in uterine and colorectal 
cancers, and no hotspot mutations have been found. Moreover, few silent mutations of ING2 
were found (59) and a study found 9.6 % of mutations of ING5 in oral squamous cancer (60). 
Overall, mutations of ING genes are not frequent in human tumors. 
Other mechanisms such as LOH (Loss of Heterozygosity) are involved in the regulation of 
ING genes in cancer. For instance, ING1 loss of expression occurs mainly at the RNA level, 
and LOH (between 55,7 % and 61,1%) have also been observed (24,28,29,61). Shen et al. 
reported that hypermethylation of ING1 promoter  in ovarian cancer (28% of the cases) is 
associated with ING1 down-regulation (62). With respect to ING2, high frequencies of LOH 
in the chromosomal region 4q32-35.1 in ameloblastoma, sporadic basal cell carcinoma and 
squamous cell carcinoma of the head and neck (30%, 46.1% and 54.6%, respectively) (24, 30, 
64) have been described. Finally, no increased methylation of ING2 promoter have been 
found in NSCLC (22). Loss of ING3 by LOH was observed in 10,2% of HHNSC (31) and in 
68% of ameloblastomas (24). The expression ING4 can also be lost by LOH, which can occur 
in 5% to 66% of cases depending on the cancer (63,64) , by abnormal transcription (65) or 
post-transcriptionnal regulation (66). In some cases it has also been reported that ING4 is 
more expressed in the cytoplasm than in the nucleus, leading to tumorigenesis, but the exact 
reason of this change of location remains to be explained (67). Various causes have been 
described to explain the dysregulation of ING5 gene expression in cancer. One of them being 
the LOH occurring in up to 68 % of cancers (24,68). In addition, it has been shown that the 
nucleocytoplasmic translocation of ING1 and ING5 may play a role in cancers (69,70). 
Indeed, ING1 and ING5 overexpression in the cytoplasm rather than in the nucleus prevents it 
from fulfilling its tumor suppressive roles such as regulating the chromatin or the DNA 
replication. Cytoplasmic expression of ING5 was positively correlated with tumor size in 
breast cancers (70).  
Thus, mechanisms for explaining loss of expression of ING genes have been described in 
cancers. However, they are not enough to explain the loss of expression of ING in the vast 
majority of cases. 
 
2. INGs post-translationnal regulation 
Several mechanisms of regulation of INGs proteins have been discovered. For example, 
SUMOylation of ING1b has been shown to affect the regulation of gene transcription such as 
ISG15 (Interferon-Stimulated Gene 15) and DGCR8 (DiGeorge Syndrome Critical Region 8) 
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(71). Moreover, Garate et al. showed that p33ING1 phosphorylation would inhibit cyclin B1 
activity, and therefore cyclin B1 dependent cell proliferation in melanoma cells (72). It also 
has been shown that Src tyrosine kinase can phosphorylate ING1 and leads to its nuclear to 
cytoplasmic relocalization resulting in an inhibition of its tumor suppressive effects (73). In 
addition, SUMOylation of ING2 enhances its association with Sin3a, leading to gene 
repression or activation (20). Another study has shown that p53 can repress ING2 promoter 
activity and its expression (74). This could be a negative feedback mechanism in response to 
p53 activation. Indeed, ING2 can interact with the acetylase p300 to enhance p53 acetylation 
and its action in apoptosis, senescence, and the cell cycle (75). Besides, Jing et al. showed that 
the degradation of ING2 can be mediated by the Smad 1 ubiquitination regulatory factor 1 
(Smurf 1) (76). Smurf1 has been reported to be upregulated in lung and gastric cancer and 
may promote oncogenesis by regulating cell cycle-related proteins such as Wee1 (77–79). 
Thus, the strong expression of Smurf1 in cancer could contribute to the degradation and 
downregulation of ING2. Concerning ING3, one study showed that it can be degraded 
through the CFSkp2-mediated ubiquitin–proteasome pathway (80). Since Skp2 expression is 
increased especially in melanoma (81,82), it could contribute to ING3 loss of expression in 
that type of cancer. Guo et al. showed that ING4 citrullination increases its degradation, 
disrupts its interaction with p53 (83). ING4 protein degradation occurs through the 
ubiquitin/proteasome pathway, and no dysregulation of it has been found in cancer (84). ING5 
can be phosphorylated by CDK2 although it has a minor effect on cell proliferation (85). 
ING5 degradation remains to be studied. 
 
II. INGs function and interaction with ncRNAs 
 
1. ING1 and ING2 interactions with miRNAs and ncRNAs 
a. Functions of ING1 and ING2  
ING1 has a role in cell proliferation by regulating cell cycle arrest, apoptosis or 
senescence (13) and subsequently is involved in cancer development (1). Moreover, ING1 can 
regulate chromatin regulation through its interaction with the mSin3a/HDAC1/2 complex 
(86), and plays a role in DNA repair (87). One report suggests that ING1 would participate in 
angiogenesis, but its involvement is less clear (27). Finally, our group showed that ING1 can 
regulate the hypoxic response by triggering hypoxia inducible factors α (HIF1α) degradation 
(88). 
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ING2 is the closest ING1 homolog leading to common properties between ING1 and 
ING2. In fact, ING2 is involved in cell cycle, senescence and apoptosis regulation (3,89). It 
also interacts with the mSin3a/HDAC1/2 complex to modulate gene expression (20), and 
participates in DNA repair through Nucleotide Excision Repair (NER) regulation (90). 
 
 
b. Regulation of miRNAs by ING1 
Interestingly, ING1 can regulate the expression of miRNAs in order to regulate gene 
expression with two discovered mechanisms. First, ING1 can play a role in miRNAs 
synthesis. Indeed, it has been shown in osteosarcoma cell lines that ING1 can regulate and 
increase through chromatin modification, the miR-203 expression (91). mir-203 has notably 
been described as a tumor suppressor in several cancer type (92–94). It also account for a 
significant proportion of the inhibitory effects of ING1 on cell proliferation by targeting 
several common mRNAs such as c-Abl oncogene 1, RB1 (RB transcriptional corepressor 1), 
or BRCA1 (BRreast CAncer 1) (91). Those genes are known to be part of cancer pathway and 
their inhibition is consistent with tumor suppressive functions of ING1. 
Furthermore, epigenetic is not the only way for ING1 to control miRNAs expression. In fact, 
a study has shown that DGCR8, a miRNA regulator protein involved in the early stages of the 
majority of miRNA processing, is negatively controlled by ING1 (95). Since miRNAs are 
usually deregulated in cancer (43), this could contribute to neoplastic transformation 
following ING1 dysfunction. Besides, ING1 is involved in apoptosis in a p53 dependent and 
independent way (12,96,97). Tran et al. demonstrated that ING1 and p53 interact to increase 
levels of large intergenic long non-coding RNA p21 (lincRNA-p21) involved in apoptosis 
(98). This could explain in part the p53-independent apoptosis mediated by ING1. Thus, the 
close relationship between ING1 and miRNAs emphasizes their role in oncogenesis and needs 
to be further explored. 
 
c. Regulation of ING1 and ING2 by miRNAs 
It has been shown that ING1 can be regulated by miRNAs. Indeed, one report described 
that ING1 is a target of the miR-371-5p in pancreatic cancer, which is associated with 
tumorigenesis and poor survival (33). However, ING1 regulation by miRNAs remains unclear 
and would require further investigation.  
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Only one recent study described ING2 regulation by a miRNA. In fact, Gao et al. 
demonstrated in silico and in vitro that ING2 is the first reported putative target of miR-8084 
in breast cancer (99). mir-8084 has been found to be upregulated in serum from breast cancer 
patient (100) and promotes the migration and invasion of breast cancer cells (99). It has been 
shown that miR-8084 down-regulates ING2, and by thus can suppress the p53 signaling 
pathway (99). miR-8084 would act as an oncomiR at least by targeting ING2 and inhibiting 
its tumor suppressive functions.  
 
2. ING3 role and ncRNAs involvement 
ING3 differs with other members of ING family in its chromosomal location (which is 
central and not telomeric) and in fact it is considered as a phylogenetic branch distinct from 
the other INGs (6). However, ING3 is also considered as a TSG since it plays a role in cell 
cycle regulation, senescence and apoptosis (10,101,102). ING3 can modulate chromatin 
modification and gene expression by interacting with the hNuA4/Tip60 complex (10). Our 
group has also shown that ING3 can also participate in the DNA damage response signaling 
(unpublished results). 
ING3 overexpression has been shown to inhibit the migration and proliferation of 
hepatocytes (103,104) and the expression of ING3 is decreased in colorectal cancer or in head 
and neck squamous cell carcinoma (HNSCC) (31,105). This suggests that ING3 plays a role 
in the progression of cancer. Indeed, decreased ING3 expression has been shown to be a 
marker of poor prognosis in several cancers (104,106,107). However, the involvement of 
ING3 in carcinogenesis has not been completely elucidated yet. Indeed, several studies 
suggest that ING3 would act as an oncogene in prostate cancer by increasing expression of 
androgen-regulated genes and is associated with poor prognosis in ERG-negative prostate 
cancer (108–110). 
The interactions between ING3 and miRNAs have been poorly documented. In colorectal 
cancer (CRC), Zhang et al. observed in CRC tissues that the lncRNA CASC7 (CAncer 
Susceptibility Candidate 7) expression was low whereas miR-21 expression was high (111). 
Moreover, they have shown in CRC cell lines that ING3 is a direct target of miR-21, known to 
act as an oncomiR in several types of cancer by targeting genes with an important role in cell 
migration, such as FZD6, or in cell proliferation such as PTEN (111–114). They demonstrated 
that CASC7 can indirectly increase ING3 expression and have tumor suppressive effects by 
sponging miR-21. 
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One report showed that in periodontitis, a non-oncogenic disease, ING3 would play a role 
and be targeted by miR-494 and miR-522, however these in silico results have not been 
confirmed in vitro (115).  
Thus, further studies concerning ING3 regulation by miRNA or ncRNAs would be needed 
in order to document their interactions in cancer and other diseases. 
 
3. ING4 and miRNAs in cancer and other diseases 
Reports show that ING4 has tumor suppressive functions. Indeed, it can regulate cell 
proliferation (116), chromatin modification since it belongs to the HBO1/JADE complex 
(117,118) and DNA replication (119). Moreover, ING4 can inhibit both cell migration 
(120,121) and neoangiogenesis (27,122). Therefore, ING4 is characterized as both a type I « 
caretaker » and type II « gatekeeper » Tumor Suppressor Gene (TSG). 
Several miRNAs have been found to decrease the expression of ING4 in cancers by 
binding to its mRNA, especially in its 3’-UTR region. ING4 has been characterized as a target 
of miR-650 which is upregulated in gastric cancer, leukemia, hepatocellular cancer, 
osteosarcoma cells and lung adenocarcinoma (123–127). In the latter case, it has been 
demonstrated that miR-650 confers chemoresistance to docetaxel, an anti-cancerous drug 
(127). miR-650 can also trigger epithelial to mesenchymal transition in breast cancer by 
targeting ING4 and NDRG2 (128). Furthermore, several other miRNAs are able to inhibit 
ING4 expression in cancers. It is the case of mir-214 in pancreatic cancers (129,130), mir-761 
in NSCLC (131), mir-330 in hepatocellular carcinoma (132) and miR-423-5p in glioblastoma 
(133). 
Beside cancers, studies have shown that miRNAs are involved in many other pathologic 
processes. For instance, miR-214 which plays a role in the development of pancreatic cancers 
is also more expressed in cardiac injuries in response to carvedilol, a drug that has protective 
properties in ischemic injuries. Overexpression of miR-214 decreases the apoptosis of 
cardiomyocytes by inhibiting ING4 (134). Moreover, one study showed that miR-361-3p, 
miR-1910-5p, miR-3691-3p could target ING4 in chronic idiopathic urticaria and active hives 
and could be used as biomarkers (135). There are some limitations to studying the interaction 
between miRNAs and ING4. In fact, one study showed by a luciferase assay, that ING4 is not 
a target of miR-2478 despite being characterized as a putative one by in silico analysis (135). 
 
4. ING5 regulation by miRNAs 
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Several studies have shown that ING5 has tumor suppressive functions. Indeed, ING5 is 
involved in the regulation of cell proliferation (136), chromatin modification since it belongs 
to the HBO1/JADE or MOZ/MORF complexes (118,137), DNA replication (10) and repair 
(138) and cell migration (139). 
Numerous reports have shown that the overexpression of miRNAs is of key importance in 
the development of several cancers. In fact, miRNA can bind to the 3’UTR of ING5 to 
degrade its mRNA and thereby increase cell proliferation. Various miRNAs are involved such 
as miR-196a in pancreatic cancer (140), miR-1307 in ovarian cancer (32), miR-24 in breast 
cancer (141) and miR-27-3p in osteosarcoma (142). In addition, two reports have shown that 
miR-331-3p and miR-181b both of which target the 3’UTR of ING5 are upregulated by the 
hepatitis B virus protein X (143,144). This overexpression can promote the proliferation of 
hepatocarcinoma cancer cells. Moreover, it has been shown that miRNAs are involved in 
chemoresistance to anti-cancerous drugs by degrading ING5 which, on the contrary, promotes 
chemosensitivity to these drugs. This is the case of miR-193a-3p in bladder cancer (138) and 
of miR-1307 in ovarian cancer (32). 
 Nevertheless, the upregulation of miRNAs is not specific to cancers. In fact, a report 
has demonstrated that miR-193 is overexpressed in response to low-level laser irradiation 
(LLLI) in multipotent stem cells resulting in ING5 inhibition and thus cell proliferation (145). 
The LLLI technique could increase the proliferation of stem cells, especially those used in 
stem cell therapy. 
 
III. Conclusion 
The members of the ING family play a critical role in cell homeostasis and their 
dysregulation can maintain oncogenesis. As a matter of fact, they appear to be down-regulated 
in several cancer (21), and associated with poor prognosis or chemoresistance 
(32,106,107,127,146,147). Moreover INGs dysregulation may have a role in other diseases. 
For instance, ING4 KO mice don’t spontaneously develop tumors but regulation of NF-κB–
mediated innate immunity is impaired (148). Thus we could hypothesize that ING4 may be 
involved in inflammatory or immunity diseases. INGs regulation in cancer and diseases has 
not been totally elucidated yet. We reported that INGs protein can be mutated (28,59–61),  
have LOH (24,30,31), or be degraded (76,77,80,84), which make them both class I TSG 
(which are lost due to mutation or deletion), and class II TSG (which are not altered at the  
DNA level) (149). Nonetheless, those mechanisms are not sufficient to explain the frequent 
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loss of expression or down-regulation of INGs in cancer. Recently, some reports described 
INGs regulations by ncRNAs. As a matter of fact, ncRNAs, and more especially miRNAs, 
have been described to be dysregulated in cancer and other diseases, with pro-oncogenic or 
tumor suppressor effects (43,44). Of note, some reported miRNA studies need to be taken 
with caution. Indeed, some studies considered candidate miRNAs based on in silico analysis 
(115,135). However, in vitro experiments did not confirm these analyzes. Thus, to 
characterize INGs as a target of a newly-found miRNAs, in silico analysis should 
systematically be confirmed by in vitro experiments.  
 
IV. Hypotheses and perspectives 
 
One intriguing hypothesis would be that ING proteins could be targeted by a same 
miRNA. miRNAs which measure approximately 20 bases bind preferentially to the 3’UTR 
sequences of transcripts thanks to a seed sequence that measures at least 6 bases (150). This 
means that theoretically a miRNA could target different INGs, but that has never been 
reported yet. When 3’ and 5’ UTR sequences of INGs are compared with Blast or Ensembl, 
3’UTR regions of several INGs share some common sequences of around 10-25 (Table 2) 
whereas not a single sequence match is observed for the 5’UTR regions. For instance, ING3 
and ING5 3’UTRs have 9 small sequences in common. Although the INGs share some small 
sequences in their 3’UTR, it should be noted that there are no significant homologies when 
looking at the whole 3’UTRs. In fact, there is a diversity of the 3’UTR sequences even when 
comparing different isoforms of the same ING gene. For instance, the ING1b 3’UTR 
sequence is included within the ING1a 3’UTR sequence but the latter is more than ten folds 
longer than the former. This variability could explain the variable expressions of the different 
ING isoforms between different tissues. When 3’UTR of ING genes are compared with other 
sequences in the genome, it is observed that the 3’UTR of ING1 shares approximately a 
hundred bases with INGX sequence. INGX is an ING1 pseudogene (2) which has never been 
shown to be translated. Its role has never been described yet. Thus, we could speculate that 
INGX could be involved in ING1 regulation of expression. However, it should be taken into 
account that INGX is much less transcribed than ING1 according to databases like ensembl.  
It has been reported that RNA hybridization within the CDS has a qualitatively similar 
effect than the 3’-UTR sites, and can induce translational repression (151). When comparing 
coding sequences of the different ING genes transcripts according to their closest homologue 
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(ING1/ING2, ING4/ING5, ING1/ING3 and ING1/INGX), homologies are more present within 
the C-terminal region of the INGs (>70%) (Fig. 3). Interestingly, the NCR (Novel Conserved 
Region) of ING1b and ING2 transcripts share 56% of homologies, which is consistent with 
the fact that they both interact with the mSin3a/HDAC complex through this NCR domain. 
Consequently, some INGs CDS could also be targeted by common miRNAs. 
Finally, whereas INGs protein can be regulated by miRNA, at least ING1 can interfere 
with miRNA synthesis (91,95), which raises the question of the other INGs involvement in 
miRNA regulation. 
Recently, therapeutics targeting miRNAs have emerged (152), hence the importance to 
understand their mechanisms of action. Indeed, since INGs proteins are TSG and are down-
regulated in many types of cancer, restoring their functions by inhibiting miRNAs could be a 
therapeutic possibility. Some studies showed that ING reintroduction mediated by adenovirus 
suppresses tumor growth, angiogenesis, enhance apoptosis and can have a synergistic effect 
with radiation therapy (153–155). Moreover, ING4 reintroduction through photothermal 
combined gene therapy showed in vitro and in vivo decreased cell viability and tumor growth 
(156). 
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Figures legends : 
 
Figure 1. INGs levels of expression in normal tissues and cancers. A) RNA level of 
expression of INGs in normal tissues and cancers based on RNAseq, according to The Human 
Protein Atlas (https://www.proteinatlas.org/) database. RNA level is expressed in RPKM 
(Read Per Kilobase per Million) in the normal tissues graph and in FPKM (number of 
Fragment Per Kilobase of exon per Million read) in the cancers graph. The size of each 
colored plot is related to each ING expression. B) Protein level of expression of INGs in 
normal tissues and cancers based on immunochemistry, according to THPA (normal tissues) 
and TCGA (cancer tissues) databases. In normal tissues, protein expression is described as 0 
(none), 1 (low), 2 (medium) or 3 (high). In cancers, each colored plot represents the 
percentage of patients with high or medium protein expression. Few antibodies have been 
validated and are reliable.  
 
Figure 2. ING genes mutation rate. Mutation rate for the different INGs according to TCGA 
database (https://portal.gdc.cancer.gov/) with tissue location. 
 
Table 1. ncRNAs targeting the INGs. Summary of the ncRNAs targeting the INGs with 
their functional consequences (oncomiR or tumor suppressor), the analysis used to associate 
miRNAs with the INGs (in silico or in vitro), and the tissue or disease studied. 
 
 
Table 2: INGs’ 3’ and 5’UTRs blast of small similar sequences. We have reported the 
length of the INGs’ 3’ and 5’ UTRs, the number of small similar sequences (10-25bp) 
between the ING transcripts and the homologies (>80%) with other gene sequences 
(https://blast.ncbi.nlm.nih.gov and http://www.ensembl.org). 
 
 
Figure 3. Homologies between different INGs transcripts. Homologies between INGs  
transcripts have been analyzed between ING1/ING2, ING1/ING3, ING1/INGX and ING4/5. 
The red color indicates an homology superior to 70%, orange an homology between 50% and 
70%, and grey an homology inferior to 50%. 
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Length
Number of small similar sequences (10-
25bp) BLAST (> 
80%)
3’UTR ING1 ING2 ING3 ING4 ING5
ING1 (NM_198218) 243 0 0 0 2
5 (INGX 
included)
ING2 (NM_001564) 144 0 1 0 1 2
ING3 (NM_019071) 2373 0 1 1 9 4
ING4 (NM_016162) 915 0 0 1 2 1
ING5 (NM_032329) 4447 2 1 9 2 100
Length
Number of small similar sequences (10-
25bp) BLAST (> 
80%)5’UTR ING1 ING2 ING3 ING4 ING5
ING1 (NM_198218) 198 0 0 0 0 2
ING2 (NM_001564) 202 0 0 0 0 1
ING3 (NM_019071) 148 0 0 0 0 2
ING4 (NM_016162) 47 0 0 0 0 2
ING5 (NM_032329) 26 0 0 0 0 0
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INGs ncRNAs Mechanisms of 
action
In silico 
analysis
In vitro analysis Tissue/disease Refs
ING1 miR-371-5p oncomiR Yes Yes Pancreas (33)
ING2 miR-8084 oncomiR Yes Yes Breast (94)
ING3
miR-21 oncomiR Yes Yes Colon (106-109)
miR-494 oncomiR Yes No Saliva (110)
miR-522 oncomiR Yes No Saliva (110)
ING4
miR-650 oncomiR Yes Yes gastric, B cells, lung, liver, 
bone, breast
(118–123)
miR-214 oncomiR Yes Yes pancreas (x2), heart (124, 125, 
129)
miR-761 oncomiR Yes Yes lung (126)
miR-330 oncomiR Yes Yes liver (127)
miR-423-5p oncomiR Yes Yes glioma cells (128)
miR-2478 Absence of 
interactions 
demonstrated by in 
vitro analysis
Yes Yes HEK293T cell (130)
miR-361-3p upregulated (could 
be used as 
biomarker)
Yes No Plasma (chronic idipathic 
urticarial)
(130)
miR-1910-5p upregulated (could 
be used as 
biomarker)
Yes No Plasma (chronic idipathic 
urticarial)
(130)
miR-3691-3p upregulated (could 
be used as 
biomarker)
Yes No Plasma (chronic idipathic 
urticarial)
(130)
ING5
miR-193 Promotes
mutipotent stem 
cells proliferation 
in response to LLLI
Yes Yes Mutipotent Stem Cells (140)
miR-193a-3p oncomiR Yes Yes Bladder (133)
miR-196a oncomiR Yes Yes Pancreas (135)
miR-331-3p oncomiR Yes Yes Liver (138)
miR-181b oncomiR Yes Yes Liver (139)
miR-1307 oncomiR Yes Yes Ovary (32)
miR-24 oncomiR Yes Yes Breast (136)
miR-27-3p oncomiR Yes Yes Bone (137)
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Highlights 
 
− INGs are tumor suppressor genes playing a crucial role in cell homeostasis 
− Multiple mechanisms may be involved in INGs loss or downregulation  
− INGs regulation is still unclear and can involve ncRNAs 
− ncRNAs may play an important role in cancer and other disease notably through INGs 
regulation. 
 
